Why Is HeartFlow (HTFL) Stock Down -14.89% Today?

Key Takeaways

• HTFL fell 14.89% to $51.00, a decline of $8.92 from the prior close of $59.92, in a session that opened sharply lower and kept sliding.
• The primary catalyst is a sell-the-news reaction to third-quarter results: revenue of $72.86 million beat expectations by roughly 12% and full-year guidance was raised, yet the stock had already rallied hard into the print.
• Secondary drivers include an implied fourth-quarter revenue figure that is essentially flat versus the third quarter, decelerating growth math, and a valuation that leaves little room for error at roughly 24x trailing sales.
• Broader market and sector conditions were neutral — large-cap healthcare and small-cap benchmarks were little changed — so the move was company-specific rather than macro-driven.
• News Significance Score: 66/100 — A major earnings beat-and-raise drove an unusually violent, roughly 5.6x-normal selloff.
• Traders are watching whether the implied fourth-quarter slowdown is conservative guidance or the start of a deceleration, plus the January plaque pricing step-up and the path to cash-flow breakeven.
• Deeper detail on Price Targets, Earnings and Forecast data is available on the dedicated pages.
• Investors seeking systematic, rules-based exposure can explore the curated Trending AI Robots list.

Opening Summary

HeartFlow, Inc. (HTFL) is a San Francisco-based medical technology company whose AI and computational fluid dynamics platform turns a single coronary CT angiography scan into a personalized 3D model of a patient's heart, helping physicians diagnose and manage coronary artery disease without invasive procedures. In late-morning trading on Friday, the stock stood at $51.00, down $8.92, or 14.89%, from Thursday's close of $59.92. The direction was decisively negative. The immediate reason cited by the market: a strong third-quarter report and a guidance raise that nonetheless failed the very high bar set by a stock trading near its 52-week high.

Earnings Beat Leaves No Room for Error

HeartFlow reported third-quarter revenue of $72.86 million, up 57.4% year over year and ahead of the roughly $65.2 million consensus. U.S. revenue rose 60%, the fastest pace in 11 quarters, global case volume climbed 89.5% to 98,155, and non-GAAP gross margin expanded to 83.8% from 76.8%. The adjusted loss of $0.03 per share was far narrower than the $0.10 consensus, while the GAAP loss was $11.5 million, or $0.13 per share.

Management raised full-year 2026 revenue guidance to $262 million to $264 million from $246 million to $250 million, implying 49% to 50% growth, lifted the plaque revenue outlook to $36 million to $37 million, and nudged non-GAAP gross margin guidance to about 82.5%. The problem lay in the arithmetic that followed: subtracting nine months of revenue from the new annual range implies fourth-quarter revenue of roughly $72.5 million to $74.5 million — barely above the third quarter. For a company that has accelerated growth for three straight quarters, an implied sequential stall is precisely the kind of deceleration that forces a repricing, even in a beat-and-raise quarter.

A Crowded Trade Unwinds

The setup mattered as much as the numbers. Shares closed Thursday at $59.92, within about 1% of the 52-week high of $60.66 set on November 11 and roughly 24% above the October 16 close of $48.29. With sentiment already positioned for another outsized beat, the earnings-driven move came from holders taking profits rather than from new negative information. The stock gapped down to $57.94 at the open — already 3.3% lower — and the selling accelerated through the morning to a session low of $50.50, a pattern consistent with momentum funds reducing exposure rather than a single fundamental shock.

Analyst Upgrades Can't Stop the Slide

Sell-side reaction was uniformly positive and notably large. Stifel lifted its target to $70 from $45 with a Buy rating, Canaccord Genuity raised its target to $69 from $56 with a Buy, and Baird moved to $68 from $56 with an Outperform. Even so, the prior consensus target sat below $52 — under the pre-earnings share price — which underlined how far valuation had run ahead of published models. Price-target increases of 20% to 55% were not enough to offset the de-rating, a sign that the market was focused on the growth trajectory rather than on analysts' marks.

Valuation, Insider Sales and the Profitability Clock

At $51, HeartFlow carries a market capitalization of roughly $4.4 billion against about $290 million in annualized revenue, a multiple that discounts years of rapid adoption. The company remains unprofitable on a GAAP basis, and management's target for cash-flow profitability sits in mid-2028, leaving a long runway of spending ahead. Insider sale disclosures have added a persistent overhang: insiders have sold roughly 332,000 shares worth about $16.6 million over the past three months, including a 38,900-share sale by the chief executive in October, all executed under pre-arranged trading plans. None of that is new, but in a high-multiple name it amplifies downside when momentum turns.

Market Context and Trading Activity

Volume was clearly elevated, with more than 370,000 shares changing hands in the first 20 minutes against a daily average near 1.6 million to 2.0 million — a pace that projects well above normal turnover. The move was not a sector event: broad healthcare benchmarks were essentially flat and small-cap indices were modestly lower, so index and sector drift explain almost none of the decline. Technically, the stock broke under its 50-day moving average near $52, surrendering a level that had contained every pullback since mid-October, while remaining far above its 200-day average around $35. That combination — a broken short-term trend inside an intact long-term uptrend — typically invites further volatility rather than immediate stabilization.

News Significance Score

A score of 0 would describe no meaningful news and a move that is routine for the stock; 100 would pair transformative news with an extreme, rare price move. This event lands at 66 out of 100. The verified news was substantial: an 11.9% revenue beat, a much narrower loss than expected, and a fourth guidance raise this year — material relative to a company of HeartFlow's size, though not transformative. The price reaction was the more unusual component. The decline was roughly 5.6 times the stock's typical absolute daily move of 2.7% over the past 60 sessions, and no session in that window produced a larger absolute move. Strong news plus a rare, outsized reaction combine into the mid-to-upper 60s.

What Comes Next for HTFL

Attention now shifts to the fourth-quarter report, expected in February, where the implied sequential flattening will be tested against actual case volume, plaque activations — management expects about 1,300 by year-end — and payer coverage that now reaches roughly 82% of U.S. lives. A plaque pricing step-up scheduled for the first quarter of 2027 is a key swing factor for the growth math. Additional P4 and DECIDE clinical data, the Boston Scientific collaboration on CT-guided PCI planning, and the rollout of PCI Navigator give the company fresh catalysts, but competitive entrants in coronary plaque and FFR analysis are multiplying. Risks include continued cash burn, potential dilution, slower hospital capital spending, reimbursement changes, and the possibility that guidance was simply conservative rather than a warning. With short interest near 8% of float, two-way volatility is likely to persist.

Trending AI Robots

Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the featured list functions as a real-time shortlist of what is working right now rather than a static catalogue. Readers looking to see which automated strategies are leading this market can review the current lineup and compare approaches.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume